How did BMRN's revenue and expenses trend in Q4 2024?

**BMRN's revenue and expenses in Q4 2024 showed strong growth and effective cost management.**

1. **Revenue Growth**: Biomarin Pharmaceutical Inc. (BMRN) reported a total revenue of $747.31 million for Q4 2024. This represents a significant increase in revenue, highlighting the company's successful market positioning and product demand.

|code|Ticker|Name|Date|Cost of Goods Sold|R&D Expenses|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|
|BMRN|BMRN.O|Biomarin|2024 Q1|1.2518E8|2.04987E8||185|
|BMRN|BMRN.O|Biomarin|2024 Q2|1.30459E8|1.83787E8||185|
|BMRN|BMRN.O|Biomarin|2024 Q3|1.88457E8|1.84901E8||185|
|BMRN|BMRN.O|Biomarin|2024 Q4|1.36139E8|1.73509E8||185|

2. **Cost Management**: The company's cost of goods sold (COGS) was $136.14 million, and research and development (R&D) expenses were $173.51 million. Despite these costs, BMRN maintained a robust profit margin, reflecting effective cost management and operational efficiency.
3. **Profitability**: BioMarin's strategic initiatives, such as the $500 million cost transformation program, have positively impacted profitability. The company reported a GAAP diluted earnings per share (EPS) of $0.55 for Q3 2024, a 162% increase year-over-year. Non-GAAP diluted EPS was $0.91, indicating strong financial performance and effective debt management.
4. **Cash Flow and Debt Management**: Biomarin's operating cash flow increased by 63% to $221 million, and the company successfully settled $495 million in convertible debt without issuing new shares, maintaining financial strength and avoiding share dilution.

In conclusion, BMRN's Q4 2024 financials demonstrate robust revenue growth, efficient cost management, and strong profitability, supported by strategic initiatives and effective debt and cash flow management.